China Pharma Holdings (CPHI) Interest Expenses (2010 - 2026)

China Pharma Holdings' Interest Expenses history runs 17 years deep, the most recent figure standing at $15758.0 for Q1 2026.

• Quarterly Interest Expenses fell 43.78% year-over-year to $15758.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $118171.0 (up 70.69% YoY) and the FY2025 annual result came in at $11.9 million, up 2281.42% from the prior year.
• Interest Expenses was $15758.0 for Q1 2026 at China Pharma Holdings, down from $54372.0 in the prior quarter.
• Across five years, Interest Expenses topped out at $21.8 million in Q3 2023 and bottomed at -$43026.0 in Q2 2022.
• A 5-year average of $1.4 million and a median of $25478.0 in 2024 frame the typical range for Interest Expenses.
• Peak annual rise in Interest Expenses reached 108634.93% in 2023, while the deepest fall reached 151.61% in 2023.
• China Pharma Holdings' Interest Expenses stood at $51297.0 in 2022, then sank by 151.61% to -$26476.0 in 2023, then surged by 179.55% to $21061.0 in 2024, then jumped by 158.16% to $54372.0 in 2025, then plunged by 71.02% to $15758.0 in 2026.
• Business Quant data shows CPHI's Interest Expenses at $15758.0 in Q1 2026, $54372.0 in Q4 2025, and $207135.0 in Q3 2025.